“Under Secretary Kennedy’s leadership, all new vaccines will undergo safety testing in placebo-controlled trials prior to ...

Several current and former FDA employees who spoke to Inside Medicine on the condition of anonymity have come to see the ...

The US Department of Health and Human Services said it will require that all new vaccines be tested in placebo-controlled ...

The potential change outlined in a statement would require all new vaccines to undergo placebo testing, sparking concerns ...

Novavax Inc. closed 72.05% short of its 52-week high of $23.86, which the company reached on June 6th.

Dr. Marty Makary, chief of the FDA, has expressed doubts about the agency approving the COVID-19 vaccine for winter, stating ...

Novavax's protein-only vaccine is once again expected to move from emergency approval to full approval status following a pause.

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Usha Lee McFarling ...

Here are eight possible indicators of how health secretary Robert F. Kennedy Jr. may handle U.S. vaccine policy in coming ...

The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve COVID-19 vaccines for next winter, citing a lack of data on booster shots.

Novavax Inc. closed 73.09% below its 52-week high of $23.86, which the company achieved on June 6th.